Advances in Antitumor Research of CA-4 Analogs Carrying Quinoline Scaffold

Overview

Journal Front Chem

Specialty Chemistry

Date 2022 Nov 17

PMID 36385996

Authors

Chao Wang

Jing Chang

Shanbo Yang

Lingyu Shi

Yujing Zhang

Wenjing Liu

Jingsen Meng

Jun Zeng

Renshuai Zhang

Dongming Xing

Affiliations

Soon will be listed here.

Abstract

Combretastatin A-4 (CA-4) is a potent inhibitor of tubulin polymerization and a colchicine binding site inhibitor (CBSI). The structure-activity relationship study of CA-4 showed that the double bond configuration and the 3,4,5-trimethoxy group on the A ring were important factors to maintain the activity of CA-4. Therefore, starting from this condition, chemists modified the double bond and also substituted 3,4,5-trimethoxyphenyl with various heterocycles, resulting in a new generation of CA-4 analogs such as chalcone, Flavonoid derivatives, indole, imidazole, etc. Quinoline derivatives have strong biological activity and have been sought after by major researchers for their antitumor activity in recent years. This article reviews the research progress of novel CA-4 containing quinoline analogs in anti-tumor from 1992 to 2022 and expounds on the pharmacological mechanisms of these effective compounds, including but not limited to apoptosis, cell cycle, tubulin polymerization inhibition, immune Fluorescence experiments, etc., which lay the foundation for the subsequent development of CA-4 containing quinoline analogs for clinical use.

Citing Articles

The effect and mechanism of novel methoxy curcumin analogs based on network pharmacology.

Xie J, Zhao Y, Liu X, Li L, Yu L, Wang M Medicine (Baltimore). 2024; 103(7):e36483.

PMID: 38363917 PMC: 10869041. DOI: 10.1097/MD.0000000000036483.

References

Kumari A, Srivastava S, Manne R, Sisodiya S, Santra M, Guchhait S . C12, a combretastatin-A4 analog, exerts anticancer activity by targeting microtubules. Biochem Pharmacol. 2019; 170:113663. DOI: 10.1016/j.bcp.2019.113663. View

Alvarez R, Aramburu L, Puebla P, Caballero E, Gonzalez M, Vicente A . Pyridine Based Antitumour Compounds Acting at the Colchicine Site. Curr Med Chem. 2016; 23(11):1100-30. DOI: 10.2174/092986732311160420104823. View

Kuo C, Hsieh H, Pan W, Chen C, Liou J, Lee S . BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004; 64(13):4621-8. DOI: 10.1158/0008-5472.CAN-03-3474. View

Li L, Wang H, Kuo S, Wu T, LEDNICER D, Lin C . Antitumor agents. 150. 2',3',4',5',5,6,7-substituted 2-phenyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J Med Chem. 1994; 37(8):1126-35. DOI: 10.1021/jm00034a010. View

Ferlin M, Bortolozzi R, Brun P, Castagliuolo I, Hamel E, Basso G . Synthesis and in vitro evaluation of 3h-pyrrolo[3,2-f]-quinolin-9-one derivatives that show potent and selective anti-leukemic activity. ChemMedChem. 2010; 5(8):1373-85. PMC: 2921709. DOI: 10.1002/cmdc.201000180. View

Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D . Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991; 83(11):757-66. DOI: 10.1093/jnci/83.11.757. View

Roehm N, Rodgers G, Hatfield S, Glasebrook A . An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods. 1991; 142(2):257-65. DOI: 10.1016/0022-1759(91)90114-u. View

Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T . Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med. 1995; 182(2):367-77. PMC: 2192111. DOI: 10.1084/jem.182.2.367. View

Hung H, Ohkoshi E, Goto M, Bastow K, Nakagawa-Goto K, Lee K . Antitumor agents. 293. Nontoxic dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate (DDB) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs. J Med Chem. 2012; 55(11):5413-24. PMC: 3375343. DOI: 10.1021/jm300378k. View

10.

Provot O, Hamze A, Peyrat J, Brion J, Alami M . Discovery and hit to lead optimization of novel combretastatin A-4 analogues: dependence of C-linker length and hybridization. Anticancer Agents Med Chem. 2013; 13(10):1614-35. DOI: 10.2174/187152061310131206162302. View

11.

Lee H, Chang J, Nien C, Kuo C, Shih K, Wu C . 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2. J Med Chem. 2011; 54(24):8517-25. DOI: 10.1021/jm201031f. View

12.

Sackett D . Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin. Pharmacol Ther. 1993; 59(2):163-228. DOI: 10.1016/0163-7258(93)90044-e. View

13.

Martin S, Reutelingsperger C, McGahon A, Rader J, van Schie R, LaFace D . Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995; 182(5):1545-56. PMC: 2192182. DOI: 10.1084/jem.182.5.1545. View

14.

Kuo S, Lee H, Juang J, Lin Y, Wu T, Chang J . Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin. J Med Chem. 1993; 36(9):1146-56. DOI: 10.1021/jm00061a005. View

15.

Li W, Shuai W, Sun H, Xu F, Bi Y, Xu J . Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site. Eur J Med Chem. 2018; 163:428-442. DOI: 10.1016/j.ejmech.2018.11.070. View

16.

Zhou Y, Yan W, Cao D, Shao M, Li D, Wang F . Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agents. Eur J Med Chem. 2017; 138:1114-1125. DOI: 10.1016/j.ejmech.2017.07.040. View

17.

Ibrahim T, Hawwas M, Malebari A, Taher E, Omar A, OBoyle N . Potent Quinoline-Containing Combretastatin A-4 Analogues: Design, Synthesis, Antiproliferative, and Anti-Tubulin Activity. Pharmaceuticals (Basel). 2020; 13(11). PMC: 7698209. DOI: 10.3390/ph13110393. View

18.

Chaudhary V, Venghateri J, Dhaked H, Bhoyar A, Guchhait S, Panda D . Novel Combretastatin-2-aminoimidazole Analogues as Potent Tubulin Assembly Inhibitors: Exploration of Unique Pharmacophoric Impact of Bridging Skeleton and Aryl Moiety. J Med Chem. 2016; 59(7):3439-51. DOI: 10.1021/acs.jmedchem.6b00101. View

19.

Perez-Melero C, Maya A, del Rey B, Pelaez R, Caballero E, Medarde M . A new family of quinoline and quinoxaline analogues of combretastatins. Bioorg Med Chem Lett. 2004; 14(14):3771-4. DOI: 10.1016/j.bmcl.2004.04.098. View

20.

Fortin S, Lacroix J, Cote M, Moreau E, Petitclerc E, C-Gaudreault R . Quick and simple detection technique to assess the binding of antimicrotubule agents to the colchicine-binding site. Biol Proced Online. 2011; 12(1):113-7. PMC: 3055821. DOI: 10.1007/s12575-010-9029-5. View